Envafolimab, The World’s First Subcutaneously Injected PD-L1 Antibody Approved by NMPA! Simcere Partners with Alphamab Oncology and 3DMed to Innovate Immunotherapy

Simcere and Shanghai Institute of Materia Medica Enter a Collaboration to Jointly Develop Next-Gen COVID-19 Oral Antiviral Treatments

IND Application for Simcere’s Independently Developed Anti-TNFR2 Antibody Accepted by CDE

Envafolimab in Combination with Lenvatinib for the Treatment of Endometrial Cancer Granted Implied License for Clinical Trials

Latest Study Data of Sanbexin^® Released at ESOC 2021

Simcere Pharmaceutical Group Announces 2021 Interim Results | Solid Revenue Growth Driven by Sanbexin^®, and Rapid Progress in Innovative R&D

Trilaciclib Granted Fast Track Designation by the U.S. FDA for Use in Combination with Chemotherapy for the Treatment of TNBC

Phase Ⅱ Clinical Data of Envafolimab in MSI-H/dMMR Solid Tumors Published in the Journal of Hematology & Oncolog

Envafolimab Obtained Its 2nd Orphan Drug Designation from the U.S. Food and Drug Administration

Simcere and Vivoryon Therapeutics Announce Strategic Regional Licensing Partnership for N3pE Amyloid-Targeting Medicines to Treat Alzheimer’s Disease in Greater China